albumin-bound paclitaxel / Generic mfg. |
| Recruiting | N/A | 200 | | | The University of Sydney, National Health Medical Research Council | Cancer, Cardio Vascular Disease | | | | |
NCT06478355: Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma(ChinECR) |
|
|
| Active, not recruiting | N/A | 800 | RoW | Immunotherapy, PD-1/PD-L1, Chemotherapy drug, TP, radiotherapy | Hebei Medical University Fourth Hospital | ESCC | 07/24 | 12/24 | | |
ChiCTR-IOR-17010687: Clinical study of first-line chemotherapy for ovarian cancer with paclitaxel and carboplatin albumin intravenous chemotherapy |
|
|
| Recruiting | N/A | 100 | | Paclitaxel intravenous combined with intraperitoneal chemotherapy ;Albumin paclitaxel combined carboplatin chemotherapy | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Shengkang hospital development center to promote the action plan of municipal hospital clinical skills and clinical disease clinical specialist three years of | ovarian cancer | | | | |
NCT02318095: Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer |
|
|
| Completed | N/A | 40 | US | Gemcitabine/nab-Paclitaxel, Radiation therapy, Sugical resection, Adjuvant chemotheapy | Duke University | Resectable Pancreatic Cancers | 11/18 | 11/22 | | |
NCT06235164: The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer |
|
|
| Active, not recruiting | N/A | 585 | RoW | immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab | Fujian Medical University | Locally Advanced Gastric Cancer | 12/22 | 12/25 | | |
ChiCTR-INR-17012555: Clinical study of neoadjuvant therapy used in borderline resectable pancreatic cancer |
|
|
| Not yet recruiting | N/A | 798 | | Perform chemotherapy with mFOLFIRNOX ;Perform chemotherapy with GEM and 5-FU ; Perform chemotherapy with GEM and Abraxane | Shanghai Changzheng Hospital affiliated to Second Military Medical University; Shanghai Changzheng Hospital, Research doctor development program of Shanghai Changzheng Hospital affiliated to Second Military Medical University | pancreatic cancer | | | | |
ChiCTR1900022192: Phase Ib trial for Neoadjuvant therapy with PD-1 Antibody (SHR-1210) and albumin-bound paclitaxel plus Gemcitabine on resectable/borderline resectable Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 26 | | Neoadjuvant therapy with PD-1 Antibody(SHR-1210) and albumin-bound paclitaxel plus Gemcitabine | Chinese PLA General Hospital (301 hospital); Level of the institution:, self-funding | Pancreatic cancer | | | | |
ChiCTR1900023370: Phase I clinical study for albumin paclitaxel and capecitabine chemotherapy combined with local radiotherapy for initial unresectable locally advanced gastric cancer or para-aortic lymph node metastasis |
|
|
| Recruiting | N/A | 24 | | albumin paclitaxel and capecitabine chemotherapy combined with local radiotherapy | West China Hospital, Sichuan University; Level of the institution:, CSPC Ouyi Pharmaceutical Co.,Ltd. | Gastric cancer | | | | |
ChiCTR1900023373: Phase I Clinical Study for Postoperative Early Stage Cervical Cancer with High Risk Factors Treated by Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy |
|
|
| Recruiting | N/A | 24 | | Albumin Paclitaxel and Cisplatin Chemotherapy Combined with Synchronous Local Radiotherapy | West China Hospital, Sichuan University; Level of the institution:, CSPC OUYI PHARMACEUTICAL CO.,LTD. | Cervical cancer | | | | |
| Completed | N/A | 206 | RoW | PD-1 inhibitor+carboplatin+albumin-bound paclitaxel | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oral Cancer | 06/22 | 06/22 | | |
ChiCTR1900027932: Pyrotinib in Combination With Albumin–Bound Paclitaxel in HER2-Positive Patients With Advanced Breast Cancer: a Multicentre Phase II Study |
|
|
| Recruiting | N/A | 79 | | Pyrotinib in combination with Albumin–Bound Paclitaxel | Shandong Institute of Cancer Prevention and Control; Shandong Institute of Cancer Prevention and Control, artial self-expenditure | breast cancer | | | | |
NCT04518800: PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 20 | RoW | Jin Youli(PEG-rhG-CSF) | Chinese PLA General Hospital | PEG-rhG-CSF, Pancreatic Cancer | 08/21 | 02/22 | | |
ChiCTR1900023657: A clinical trial for apatinib combination with nab-paclitaxel /cisplatin in the treatment of NSCLC |
|
|
| Not yet recruiting | N/A | 60 | | Apatinib 250mg Po qd nab-paclitaxel: 100mg/m2 iv d1, 8, 15 cisplatin: 75mg/m2 d1 q3w, 4-6 cycles | Tangshan People's Hospital; Tangshan People's Hospital, no | non small cell lung cancer | | | | |
ChiCTR1900028212: A multicenter, prospective, single-arm, exploratory clinical study of neoadjuvant therapy of her2-positive breast cancer with pyrotinib maleate tablets combined with paclitaxel for injection (albumin bound) |
|
|
| Recruiting | N/A | 90 | | pyrotinib maleate tablets combined with albumin paclitaxel combined with epirubicin and cyclophosphamide | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University, Self raise independently | breast cancer | | | | |
ChiCTR1900025919: Clinical efficacy of paclitaxel albumin combined with carboplatin in neoadjuvant chemotherapy for locally advanced cervical cancer and its effect in PDX model of cervical cancer |
|
|
| Not yet recruiting | N/A | 200 | | Albumin-bound Paclitaxel combined with Carboplatin ;Paclitaxel combined with Carboplatin | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, Heathco - stone cancer research foundation | cervical cancer | | | | |
NCT06378840: the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Nab-paclitaxel/Platinum, Sintilimab | RenJi Hospital | Locally Advanced Cervical Carcinoma, Concurrent Chemoradiotherapy, Immunotherapy | 12/24 | 12/24 | | |
PC-CURE-1, UMIN000035668: Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapy |
|
|
| Completed | N/A | 360 | Japan | | Federation of Asian Clinical Oncology (FACO), Federation of Asian Clinical Oncology (FACO) | Unresectable pancreatic cancer | | | | |
ChiCTR2000032509: Efficacy and safety of Tislelizumab plus chemotherapy as first-line treatment in elderly advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 36 | China | Tislelizumab plus chemotherapy | Jiansu Cancer Hospital ; Jiansu Cancer Hospital, self-financing | Non small cell lung cancer | | | | |
ChiCTR2100045484: Nituzumab-albumin-bound paclitaxel and cisplatin therapy Single arm study of recurrent/metastatic cervical squamous cell carcinoma |
|
|
| Recruiting | N/A | 30 | | Nituzumab treatment regimen | Baotou Tumor Hospital; Baotou Tumor Hospital, Enterprise financing | Recurrent/metastatic cervical squamous cell carcinoma | | | | |
CPOG-007-A, ChiCTR1900024176: SHR- 1210 combined with Paclitaxel (Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer |
|
|
| Recruiting | N/A | 20 | | SHR-1210, 200mg, D1; Paclitaxel (Albumin Bound), 125 mg/m2, D1, 8; Gemcitabine, 1000mg/m2, D1, 8; Every 21 days as a cycle. | Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | pancreatic cancer | | | | |
NCT06378580: The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | N/A | 72 | RoW | Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX | Luo Cong | Pancreatic Cancer | 07/23 | 04/24 | | |
ChiCTR2000034609: Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin in the treatment of platinum resistant or refractory ovarian cancer: an open, single arm, phase II prospective study |
|
|
| Recruiting | N/A | 51 | | Efficacy and safety of albumin bound paclitaxel combined with pegylated liposome doxorubicin | Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital, CSPC OUYI PHARMACEUTICAL CO.,LTD. | ovarian cancer | | | | |
ChiCTR1900025574: An observational study for the efficacy and safety of apatinib combined with albumin-bound taxol in the second-line treatment of advanced gastric cancer |
|
|
| Recruiting | N/A | 35 | | Apatinib combined with albumin-bound paclitaxel | The First Affiliated Hospital of Suzhou University; The First Affiliated Hospital of Suzhou University, Self financing | Gastric cancer | | | | |
ChiCTR1900027332: A single-center and single-arm clinical study of neoadjuvant nab-paclitaxel combined with carboplatin therapy in patients with triple-negative or HER2-positive breast cancer |
|
|
| Not yet recruiting | N/A | 60 | | nab-paclitaxel combined with carboplatin | West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSPC Ouyi Pharmaceutical Co., Ltd. | breast cancer | | | | |
ChiCTR2000038254: An exploratory study of Camrelizumab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer |
|
|
| Not yet recruiting | N/A | 41 | | Camrelizumab: 200mg, iv, 30min, q2w Chemotherapy: nab-paclitaxel 80mg/m2 d1, 8, 15 iv q4w, until death or intolerable toxicity treatment | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-financing | Ovarian cancer | | | | |
NCT04603586: Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses |
|
|
| Recruiting | N/A | 138 | RoW | SBRT, Chemotherapy | Changhai Hospital | Treatment | 10/22 | 10/23 | | |
NCT04423731: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | N/A | 251 | Europe | Folfirinox, Gemcitabine/nab-paclitaxel, Gemcitabine, 5-FU (fluorouracil) and leucovorin, FLOX | Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, Helse Stavanger HF | Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatectomy | 10/22 | 12/25 | | |
ChiCTR1900026622: A multicenter-center, one-arm exploratory clinical study for Apatinib mesylate combined with albumin-bound taxol in the treatment of patients with recurrent/metastatic nasopharyngeal carcinoma |
|
|
| Not yet recruiting | N/A | 60 | | Apatinib combined with albumin-bound paclitaxel | Department of Oncology, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University; Department of Oncology, Guigang City People’s Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Jiangsu hengrui co. LTD | nasopharyngeal carcinoma | | | | |
ChiCTR2000037723: A prospective, randomized, double-blinded, multi-center clinical trial to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer |
|
|
| Not yet recruiting | N/A | 401 | | PD-1 antibody (Camrelizumab) combined with paclitaxel (albumin- binding) and gemcitabine ;Placebo combined with paclitaxel (albumin- binding) and gemcitabine | Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | pancreatic cancer | | | | |
ChiCTR2100044219: A prospective phase I clinical trial of paclitaxel for injection (albumin-binding) intraperitoneal perfusion combined with systemic chemotherapy for peritoneal metastasis of pancreatic cancer |
|
|
| Recruiting | N/A | 18 | | intraperitoneal perfusion of albumin paclitaxel ;intraperitoneal perfusion of albumin paclitaxel | West China Hospital, Sichuan University; West China Hospital, Sichuan University, No | pancreatic cancer | | | | |
ChiCTR2000039418: A prospective, real-world clinical study of albumin-bound paclitaxel combined with Sindilizumab in the treatment of non-small cell lung cancer |
|
|
| Recruiting | N/A | 400 | | Immunotherapy combined with chemotherapy or chemotherapy | The Second People's Hospital of Neijiang; The Second People's Hospital of Neijiang, Wu Jieping medical foundation | Non-small cell lung cancer | | | | |
ChiCTR2000039253: A single-center, randomized controlled clinical study of nab-paclitaxel combined with capecitabine versus capecitabine monotherapy for paclitaxel/docetaxel resistant advanced breast cancer |
|
|
| Recruiting | N/A | 92 | | Paclitaxel combined with Capecitabine ;Capecitabine | Shanghai Cancer Center affiliated to Fudan University; Shanghai Cancer Center affiliated to Fudan University, CSPC Ouyi Pharmaceutical Co., Ltd. | Breast cancer | | | | |
ChiCTR2100051909: Sintilimab combined with albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: a retrospective study |
|
|
| Recruiting | N/A | 30 | | None | He'nan Provincial People's Hospital; He'nan Provincial People's Hospital, Fund of He'nan Provincial People's Hospital 23456 | esophageal squamous cell carcinoma | | | | |
ChiCTR2200055659: A prospective clinical study of PD-1 inhibitor combined with albumin-paclitaxel + oxaliplatin + S-1 chemotherapy for perioperative treatment of locally advanced gastric cancer |
|
|
| Recruiting | N/A | 30 | | | Cangzhou Central Hospital; Cangzhou Central Hospital, Wu Jieping Medical Foundation | Gastric Cancer | | | | |
CamPacBTC, ChiCTR2100042316: Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study |
|
|
| Recruiting | N/A | 63 | | camrelizumab + nab-paclitaxel | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Funds raised independently | biliary tract cancer | | | | |
ChiCTR2100042236: A prospective, open-label, single arm study evaluating the efficacy of anlotinib combined with albumin-bound paclitaxel and carboplatin in neoadjuvant treatment of triple-negative breast cancer |
|
|
| Recruiting | N/A | 53 | | Anlotinib+nab-paclitaxel+carboplatin | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, ChiaTai Tian Qing Pharmaceutical Company | Triple negative breast cancer | | | | |
ChiCTR2200058126: II clinical study of carrelizumab, albumin paclitaxel and apatinib combined with or without Fuzi Lizhong Pill in the treatment of unresectable locally advanced/metastatic pancreatic cancer |
|
|
| Not yet recruiting | N/A | 30 | | NA | Second People's Hospital of Anhui Province; 安徽省合肥市北二环砀山路1868号, Self-raised | pancreatic cancer | | | | |
ChiCTR2100045209: Exploratory clinical study of PD-1 inhibitor combined with chemotherapy (albumin paclitaxel combined with carboplatin for three weeks) in the treatment of advanced non-small cell lung cancer |
|
|
| Not yet recruiting | N/A | 30 | | PD-1 inhibitor + chemotherapy | The Fifth Affiliated Hospital of Sun Yat-Sen University; The Fifth Affiliated Hospital of Sun Yat sen University, self-funded | lung cancer | | | | |
ChiCTR2100044498: hyperthermic intraperitoneal chemotherapy with albumin paclitaxel for the prevention of peritoneal metastasis in patients with locally advanced gastric cancer after surgery: a nonrandomized, open, multicenter study |
|
|
| Recruiting | N/A | 30 | | intraperitoneal paclitaxel thermoperfusion chemotherapy | The Affiliated Hospital of Jiangnan University; Affiliated Hospital of Jiangnan University, self-funded | gastric cancer | | | | |
ChiCTR2100046353: Neoadjuvant treatment of locally advanced resectable stage III esophageal squamous cell carcinoma with Camrelizumab combined with chemotherapy |
|
|
| Recruiting | N/A | 60 | | Camrelizumab + albumin paclitaxel + nedaplatin | Anhui Cancer Hospital; Anhui Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd | Esophageal Squamous Cell Carcinoma | | | | |
ChiCTR2000032955: Efficacy and safety of anti-PD-1 monoclonal antibody with concurrent chemoradiotherapy for potentially resectable pancreatic cancer |
|
|
| Recruiting | N/A | 25 | | PD-1 mAb, nab-paclitaxel, gemcitabine and radiotherapy | Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Self-financing | Pancreatic cancer | | | | |
BETTER, NCT05407155: Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 56 | NA | bevacizumab plus nab-paclitaxel and platinum | Fudan University | Non-small Cell Lung Cancer Metastatic | 06/23 | 06/24 | | |
NCT05132790: Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment |
|
|
| Active, not recruiting | N/A | 24 | RoW | SHR-1316 at a dose 20mg/kg q3w, SHR6390 at a dose of 150mg orally, daily, SBRT | Shengjing Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 12/24 | 12/28 | | |
ERI-Based-01, NCT05953909: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (). |
|
|
| Active, not recruiting | N/A | 120 | RoW | Eribulin-Based Regimen, Not Applicable since observational study, nab-paclitaxel based regimen, Other Chemotherapy Regimen | Fujian Cancer Hospital | Breast Cancer | 08/23 | 08/23 | | |
ChiCTR2000030250: Phase II clinical trial of albumin-bound paclitaxel plus gemcitabine in the treatment of metastatic/locally unresectable soft tissue sarcoma: a single-center, open, single-arm study |
|
|
| Recruiting | N/A | 35 | | albumin-bound paclitaxel plus gemcitabine | Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University, self-raised | Soft tissue sarcoma | | | | |
ChiCTR2200061128: Single center, single arm, phase II clinical trial of albumin-bound paclitaxel combined with cisplatin as neoadjuvant therapy for locally advanced cervical cancer |
|
|
| Recruiting | N/A | 50 | | albumin-bound paclitaxel combined with cisplatin | Cancer Hospital, Chinese Academy of Medical Sciences; Cancer Hospital, Chinese Academy of Medical Sciences, CSPC Ouyi Pharmaceutical Co., Ltd. | cervical cancer | | | | |
ChiCTR2100051515: Clinical study of nituzumab combined with albumin paclitaxel combined with teggio in the treatment of locally advanced or metastatic pancreatic cancer |
|
|
| Not yet recruiting | N/A | 33 | | No | Baotou Tumor Hospital; Baotou Tumor Hospital, Enterprise funding | pancreatic cancer | | | | |
ChiCTR2100052118: Second-Line treatment of nab-paclitaxel combined with sintilimab in advanced biliary tract cancer: an exploratory study |
|
|
| Not yet recruiting | N/A | 63 | | nab-paclitaxel + sintilimab | West China Hospital of Sichuan University; West China Hospital of Sichuan University, self-raised | biliary tract cancer | | | | |
NCT05677217: Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | | CHA University | Locally Advanced Cholangiocarcinoma | 09/24 | 11/24 | | |
NCT04365049: Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | Radiotherapy, Nab-paclitaxel, Gemcitabine, Camrelizumab | Sun Yat-sen University | PDAC - Pancreatic Ductal Adenocarcinoma | 12/23 | 12/23 | | |
NCT05740995: Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 40 | RoW | neoadjuvant anti-PD-1 plus chemotherapy | Shanghai Zhongshan Hospital | Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | 12/23 | 12/28 | | |
ChiCTR2100054202: A clinic trial of PD-1 blockade combined with albumin paclitaxel and gemcitabine in the hepatic metastasis of pancreatic ductal adenocarcinoma |
|
|
| Not yet recruiting | N/A | 40 | | Camrelizumab + Gemcitabine + albumin bound paclitaxel ;Gemcitabine + albumin bound paclitaxel | The First Affiliated Hospital of Naval Medical University, Changhai Hospital; The First Affiliated Hospital of Naval Medical University, Changhai Hospital, Suzhou Shengdia Biopharmaceutical Co., Ltd. | Hepatic metastasis of pancreatic ductal adenocarcinoma | | | | |
NCT04047953: Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma |
|
|
| Recruiting | N/A | 95 | RoW | Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1, Paclitaxel (albumin-bound) + Oxaliplatin + S-1, Nab-paclitaxel + Oxaliplatin + S-1 | Peking University Cancer Hospital & Institute | Gastric Adenocarcinoma | 12/23 | 11/26 | | |
PARC, NCT04894643: Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer |
|
|
| Recruiting | N/A | 10 | Europe | Proton Ions, Nab-PACLitaxel, Abraxane®, Gemcitabine, Capecitabine, Surgical resection of the pancreas (when feasible) | EBG MedAustron GmbH, Landesklinkum Wiener Neustadt | Pancreatic Cancer, Proton Therapy | 12/24 | 12/26 | | |
NCT04871321: Biomarker Discovery in Patients With Advanced Biliary Tract Cancer |
|
|
| Recruiting | N/A | 120 | RoW | nab-paclitaxel plus gemcitabine-cisplatin, immunohistochemistry, NGS, RNA-sequencing, Liquid biopsy | CHA University, Dong-A Pharmaceutical | Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer | 03/24 | 12/24 | | |
NCT06267144: Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 20 | RoW | Sintilimab plus chemotherapy | The First Hospital of Jilin University | Lung Cancer | 06/25 | 12/25 | | |
PACsign, NCT05475366: Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures |
|
|
| Recruiting | N/A | 62 | Europe | Clinical value of 5 transcriptomic signatures to personalize the therapeutic decision for L1 in PDAC, Biomarkers of tumor signatures (translational studies) | Institut Curie | Carcinoma, Pancreatic Ductal, Prognosis | 12/26 | 12/26 | | |
NCT05959395: Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors |
|
|
| Recruiting | N/A | 5 | US | VectRx Thermal Therapy | NeoTherma Oncology, University of Maryland, Baltimore, Databean | Pancreatic Cancer | 02/24 | 04/24 | | |
ChiCTR2000029854: Albumin Paclitaxel plus S-1 and Anlotinib as First-Line Chemotherapy for Metastatic or Unresectable Locally Advanced Biliary Tract Carcinomas: a Phase II Clinical Trial |
|
|
| Not yet recruiting | N/A | 30 | | nab-paclitaxel plus S-1 and anlotinib | Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center; Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, self-financing | Biliary Tract Carcinomas | | | | |
NCT04631445: Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer |
|
|
| Active, not recruiting | N/A | 32 | US | Ketogenic Diet | Translational Drug Development, Translational Genomics Research Institute | Metastatic Pancreatic Ductal Adenocarcinoma | 12/24 | 04/25 | | |
NCT05378334: Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients |
|
|
| Recruiting | N/A | 82 | RoW | ICI, Chemotherapy, Placebo, Bone-protecting and Mass-dispersesing Decoction | Guangzhou University of Traditional Chinese Medicine | Non-small Cell Lung Cancer | 03/24 | 03/25 | | |
| Recruiting | N/A | 153 | Europe | various neoadjuvant therapies | IRCCS San Raffaele | Bladder Cancer | 03/26 | 03/27 | | |
NCT06349044: A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. |
|
|
| Recruiting | N/A | 120 | RoW | Hypofractionated radiotherapy/SBRT(5-10Gy/fx,3-5 fx), Anti-PD-1 monoclonal antibody, Oxaliplatin and Capecitabine, Anti-VEGF 15mg/kg, Anti-VEGF 7.5mg/kg, Gemcitabine and Cisplatin | Zhejiang Cancer Hospital | Her-2 Negative Adenocarcinoma of the Gastro-oesophageal Junction/Gastric Adenocarcinoma, Hepatocellular Carcinoma, Biliary Tract Carcinoma, Colorectal Adenocarcinoma | 12/25 | 12/25 | | |
SMART, NCT04276857: Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 27 | NA | Irreversible electroporation (NanoKnife® ), FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) or gemcitabine/nab-paclitaxel | University of Saskatchewan | Locally Advanced Pancreatic Cancer, Irreversible Electroporation | 03/26 | 03/26 | | |
NCT06494514: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer |
|
|
| Recruiting | N/A | 40 | RoW | nal-IRI+Oxaliplatin+5-FU/LV+PD-1, Gemcitabine + albumin-paclitaxel+PD-1 | Du Juan | Locally Advanced Pancreatic Cancer | 04/27 | 04/27 | | |
ChiCTR2000031511: Efficacy and safety of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in elderly patients with locally advanced nasopharyngeal carcinoma: a prospective II phase clinical trial |
|
|
| Recruiting | N/A | 36 | | induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy | Affiliated Cancer Hospital of Guangzhou Medical University; Affiliated Cancer Hospital of Guangzhou Medical University, Self-raised | nasopharyngeal carcinoma | | | | |
NCT06417892: Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma |
|
|
| Not yet recruiting | N/A | 60 | NA | PD-1inhibitor, PD-1 antibody | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Gastric Cancer | 05/26 | 11/26 | | |
NCT06420908: Adebrelimab Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) |
|
|
| Not yet recruiting | N/A | 30 | NA | Adebrelimab+TP/FP+ radiation therapy, Adebrelimab+FP/TP+ radiation therapy | Hebei Medical University Fourth Hospital | Esophageal Squamous Cell Carcinoma | 05/26 | 05/27 | | |
ChiCTR2200061237: An exploratory clinical study of penpulimab combined with anlotinib and albumin paclitaxel in the treatment of recurrent and metastatic head and neck squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 30 | | penpulimab combined with anlotinib and albumin paclitaxel | Qingdao Municipal Hospital East Branch; Qingdao Municipal Hospital East Branch, Beijing Kangmeng Foundation | head and neck squamous cell carcinoma | | | | |
NCT03393741: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
|
|
| Terminated | N/A | 5 | US | Taxane, paclitaxel, nab-paclitaxel, docetaxel, Vinorelbine, vinca alkaloid, Ixabepilone, epothilone, Eribulin, halichondrins, Chemotherapy | University of Wisconsin, Madison, National Cancer Institute (NCI) | Breast Cancer, Breast Neoplasms | 02/24 | 02/24 | | |
NCT06496724: A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 1 | RoW | Albumin paclitaxel/neutrophil drug | JIANG LONGWEI, China Pharmaceutial University | Breast Cancer | 06/25 | 07/25 | | |
ctDNA, NCT06103890: Dynamic Monitoring in Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 100 | RoW | | Hebei Medical University Fourth Hospital, Handan Central Hospital, Xingtai People's Hospital | Esophageal Squamous Cell Carcinoma | 06/24 | 07/25 | | |
ChiCTR2300074794: A prospective, one-arm, two-cohort clinical study of autologous γδT adoptive immune cells combined with gemcitabine-based standard first-line chemotherapy in the treatment of inoperable or metastatic biliary pancreatic malignancies |
|
|
| Recruiting | N/A | 40 | | γδT cells+ gemcitabine+ tegafur; γδT cells+ gemcitabine+ Albumin bound paclitaxel | General Hospital of the Northern Theater Command of the Chinese People's Liberation Army; General Hospital of the Northern Theater Command of the Chinese People's Liberation Army, Liaoning Provincial Science and Technology Plan Project | Biliary pancreatic malignancy | | | | |
NCT06486545: Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer |
|
|
| Not yet recruiting | N/A | 18 | NA | Irinotecan Hydrochloride Liposome Injection;Paclitaxel For Injection (Albumin Bound) | Hunan Cancer Hospital | Advanced Gastric Cancer | 07/25 | 01/26 | | |
ChiCTR2300069581: A prospective observational study of Sulfatinib plus albumin paclitaxel and gemcitabine regimen for transformation therapy of locally advanced pancreatic cancer |
|
|
| Recruiting | N/A | 40 | | Sofantinib combined with albumin bound paclitaxel and gemcitabine hydrochloride | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, self-funding | Pancreatitc cancer | | | | |
| Recruiting | N/A | 300 | Europe | Gemcitabine, Folfirinox, Gemcitabine - nab-paclitaxel, Fluorouracil, FLOX, 5-FU, 5-Fluorouracil | Lund University | Periampullary Adenocarcinoma, Periampullary Cancer, Pancreatic Cancer | 09/26 | 09/27 | | |
NCT06575322: Effects of Neoadjuvant Therapy With Carboplatin, Paclitaxel Combined With Anti-PD-1 Drugs on Pain, Anxiety and Depression in Patients With Resectable Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 302 | RoW | Carboplatin( neoadjuvant), Paclitaxel (neoadjuvant), Anti-PD-1 Drugs, Surgical resection | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Head and Neck Squamous Cell Carcinoma | 09/26 | 03/27 | | |
NCT02921022: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma |
|
|
| Active, not recruiting | N/A | 110 | US | Gemcitabine, Nab-paclitaxel, PEGPH20 | Memorial Sloan Kettering Cancer Center, Halozyme Therapeutics, Miami Cancer Institute | Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | 10/25 | 10/25 | | |
NCT06636591: Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer |
|
|
| Not yet recruiting | N/A | 14 | RoW | Device: Multimodal Tumor Thermal Therapy System Drug: Camrelizumab Drug: Nab paclitaxel Drug: Carboplatin Drug: Epirubicin Drug: Cyclophosphamide, Device: Multimodal Tumor Thermal Therapy System Drug: SHR1316 Drug: Nab paclitaxel Drug: Carboplatin | Fudan University | Breast Cancer Female, HER2-negative Breast Cancer | 02/25 | 10/26 | | |
EF-001, NCT06649448: A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. |
|
|
| Not yet recruiting | N/A | 200 | RoW | Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel, Cisplatin/pemetrexed or Carboplatin/pemetrexed, TP regimen | Shandong Cancer Hospital and Institute | Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF | 12/25 | 05/26 | | |
| Not yet recruiting | N/A | 48 | NA | surgery, Benmelstobart, tegafur, oxaliplatin, albumin paclitaxel | Xijing Hospital | Gastric Cancer | 07/26 | 12/26 | | |
NCT06658951: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | N/A | 30 | RoW | Anti-HER2 CAR-T cells | UTC Therapeutics Inc., The First Affiliated Hospital of Zhengzhou University | HER2-positive Advanced Malignant Solid Tumors | 11/26 | 11/27 | | |
| Recruiting | N/A | 100 | RoW | Drug guided by Mini-PDX/PDX, Mini-PDX/PDX | Changhai Hospital | Pancreatic Cancer | 12/24 | 12/24 | | |
NCT05601323: A Study of Suizenji in Patients With Unresectable Pancreatic Cancer |
|
|
| Recruiting | N/A | 90 | Japan | Suizenji, Nal-IRI/FL, mFOLFIRINOX, Gem/nab-PTX | SONIRE Therapeutics Inc. | Unresectable Pancreatic Cancer | 10/25 | 10/25 | | |
ChiCTR2400079595: Envafolimab combined with chemotherapy for preoperative neoadjuvant treatment of non-small cell lung cancer patients:a prospective, single arm, exploratory clinical study |
|
|
| Recruiting | N/A | 25 | | During the preoperative neoadjuvant treatment period, subjects will receive 3-4 cycles of preoperative neoadjuvant treatment: Envolizumab 300mg, Q3W, subcutaneous injection; Platinum containing dual drug chemotherapy Q3W, administered on the first day of each cycle. The chemotherapy regimen should refer to the guidelines or clinical experience to choose platinum+pemetrexed/docetaxel/albumin paclitaxel/paclitaxel.Subjects underwent preoperative imaging evaluation and surgical indication evaluation 3-5 weeks after the end of their last medication before surgery. After completing 3-4 cycles of neoadjuvant therapy, subjects who still have surgical indications will undergo radical surgery with complete resection defined by NSCLC according to the World Lung Cancer Research Association standards within 4-6 weeks. | Henan Provincial People's Hospital; Henan Provincial People's Hospital, Beijing Bethune Charitable Foundation | NSCLC | | | | |
| Not yet recruiting | N/A | 60 | NA | Carrilizumab, Albumin-bound paclitaxel, Apatinib | First Affiliated Hospital Xi'an Jiaotong University | Cholangiocarcinoma | 01/25 | 01/26 | | |
neoTAPPL, ChiCTR2300071925: A prospective, single-arm, exploratory study of the efficacy and safety of penpulimab injection in combination with albumin paclitaxel, and carboplatin as neoadjuvant therapy for triple-negative breast cancer |
|
|
| Recruiting | N/A | 46 | | penpulimab+albumin paclitaxel+carboplatin | Chinese People's Liberation Army Army 958 Hospital ; Chinese People's Liberation Army Army 958 Hospital, Self-raising | Triple negative breast cancer | | | | |
ChiCTR2200060217: A randomized controlled study of a combination of internal and external treatments for albumin paclitaxel-related peripheral neurotoxicity |
|
|
| Not yet recruiting | N/A | 120 | | Oral herbal group alone ;Bloodletting group alone ;Chinese medicine combined with four end bloodletting groups ;Blank control group | Shanxi Institute of Traditional Chinese Medicine; Shanxi Institute of Traditional Chinese Medicine, None | Peripheral neurotoxicity due to albumin paclitaxel | | | | |
ChiCTR2300076572: Immunotherapy combined with hypofractionated SBRT, antivascular targeting and low-dose chemotherapy for the first-line treatment of non-sensitive gene mutant advanced NSCLC: An exploratory clinical study |
|
|
| Recruiting | N/A | 42 | | SBRT, Toripalimab, Anlotinib, Albumin bound paclitaxel, probiotics, traditional Chinese medicine, GM-CSF | Fuzhou Pulmonary Hospital of Fujian; Fuzhou Pulmonary Hospital of Fujian, None | Non-small cell lung cancer | | | | |
ChiCTR2300071563: A phase Ⅱ study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer |
|
|
| Recruiting | N/A | 29 | | Surufatinib :250mg QD P.O, , Zimberelimab :360mg I.V D1 , , nab-paclitaxel:100mg/m2 I.V D1,D8. | Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University, Self-financing | TNBC | | | | |
ChiCTR2400080485: Envafolimab combined with Irinotecan or albumin-paclitaxel and Chidamide as second-line therapy in advanced and metastatic gastric cancer: A single-arm, exploratory, phase 2 trial |
|
|
| Recruiting | N/A | 30 | | chidamide + Envafolimab + irinotecan or albumin-paclitaxel | First affiliated hospital of Soochow university; First affiliated hospital of Soochow university, self-finance | gastric cancer | | | | |
ChiCTR2300077907: A prospective, single-arm clinical study of the efficacy and safety of Icaritin in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma not previously treated with systemic therapy |
|
|
| Recruiting | N/A | 20 | | Icaritin in combination with gemcitabine and nab-paclitaxel | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Company-funded | pancreatic cancer | | | | |
ChiCTR2300074055: Clinical study of zimberelimab combined with gemcitabine and albumin-paclitaxel in first-line treatment of patients with relapsed or metastatic pancreatic cancer |
|
|
| Recruiting | N/A | 50 | | Patients will be treated with Zimberelimab combined with gemcitabine and albumin-paclitaxel. The dose of Zimberelimab was 360mg, Q3W. Gemcitabine was administrated through intravenous infusion longer than 30min at a dose of 1000mg/m2, Q3W. And dose of albumin-paclitaxel is 125mg/m2, Q3W, through intravenous infusion longer than 30min. | Shandong Provincial Hospital; Shandong Provincial Hospital, None | Recurrent or metastatic pancreatic cancer | | | | |
ChiCTR2200063254: A single arm, multi-center, open lable, exploratory study of Tirelizumab combined with Nab-Paclitaxel and Gemcitabine in the treatment of patients with advanced biliary tract cancer |
|
|
| Not yet recruiting | N/A | 30 | China | Tirelizumab + Nab-Paclitaxel + Gemcitabine | Shanghai Xuhui Central Hospital ; Shanghai Xuhui Central Hospital, BeiGene (Beijing) Co., Ltd.; Qilu Pharmaceutical Co., Ltd. | biliary tract cancer | | | | |
NCT06109454: Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery |
|
|
| Recruiting | N/A | 240 | RoW | Huaier granule, Z20000109(NMPA Approval Number), Control | Liaoning Tumor Hospital & Institute, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Non-small Cell Lung Cancer | 09/25 | 10/28 | | |
| Recruiting | N/A | 100 | Europe | Tissue Immune Profile | Fondazione per la Medicina Personalizzata, University of Roma La Sapienza | Metastatic Triple-negative Breast Cancer | 09/25 | 09/25 | | |
NCT06080620: The Choice of Treatment Methods and Efficacy of LABC |
|
|
| Recruiting | N/A | 50 | RoW | Modified radical mastectomy for breast cancer, neoadjuvant therapy, Systematic treatment | Peking Union Medical College Hospital | Locally Advanced Breast Cancer | 10/25 | 08/26 | | |
ChiCTR2300078092: Adebrelimab combined with neoadjuvant chemotherapy in locally advanced cervical cancer |
|
|
| Recruiting | N/A | 30 | | adebrelimab combined with albumin paclitaxel and cisplatin(Q3W, 3 Cycles)→Radical surgery | Lianyungang First People's Hospital; Lianyungang First People's Hospital, self-raised | cervical cancer | | | | |
ChiCTR2300076482: An open-label, single-center, investigator-initiated, clinical study to evaluate the safety and efficacy of multi-cluster target-specific MCTL combined with AG in the therapy of advanced pancreatic cancer |
|
|
| Not yet recruiting | N/A | 20 | | Subjects were treated with AG on days 1 and 8 of each cycle with albumin-bound paclitaxel 125mg/m2 intravenous infusion. Gemcitabine 1000mg/m2 intravenously (greater than 30min).On the first day of the first treatment cycle, blood (white blood cells >= 2.0×10^8) of the subjects were collected for the preparation of MCTL cells in the treatment cycle, and MCTL cells were induced and cultured using the detected cluster targets. MCTL cells were transfused on days 16 and 17.Cluster target-specific MCTL cells were transfused twice per treatment cycle with 100ml normal saline for re-suspension and the minimum number of transfused cells was 1×10^9, all of which were administered intravenally (no prophylactic medication was required). After the transfusion device was connected to the normal saline tube, cell transfusions were performed at a drop rate of 20-40 drops/min. If there is no special reaction after 10min, change the drop rate to 60-80 drops/min (within 30min). Gently squeeze the bottom of the transfer bag every 5-10 minutes during the return process to re-suspend the precipitated cells. The cells were rinsed with 0.9% normal saline 30-50 ml before and after transfusions, and fixed with infusion strips after transfusions. | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, The Central Government Guides Local Science and Technology Development Projects, China | pancreatic cancer | | | | |
ChiCTR2400082534: A prospective, single arm, multicenter, phase II clinical study of the combination of anlotinib and albumin bound paclitaxel for second-line treatment of advanced gastric cancer |
|
|
| Not yet recruiting | N/A | 40 | | anlotinib combined with albumin bound paclitaxel | Chizhou people's Hospital, Anhui Province; Chizhou people's Hospital, Anhui Province, Hospital subsidies and self financing | Advanced gastric cancer | | | | |